<DOC>
	<DOCNO>NCT03093064</DOCNO>
	<brief_summary>Schizophrenia affect significant proportion population current level understand illness inadequate treat effectively . Converging line evidence suggest neuroinflammation occur schizophrenia , specifically over-activity brain-resident immune cell call microglia . It however unclear whether activate microglia play primary role schizophrenia , whether secondary phenomenon pathophysiological significance . The investigator therefore plan test effect monoclonal antibody ( natalizumab ) psychotic symptom cohort first episode psychosis patient .</brief_summary>
	<brief_title>Inflammatory Response In Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Aged 1850 year 2 . Diagnosis schizophrenia psychotic disorder ( Diagnostic Statistical Manual Mental Disorders5 ( DSM5 ) ; 3 . Symptomatic , define one positive symptom &gt; 3 AND one negative symptom &gt; 3 Positive Negative Syndrome Scale ( PANSS ) ; 4 . No acute relapse psychiatrically stable &gt; 1 month screening ; Exclusion criterion : 1 . History significant comorbid CNS disorder ( include significant head trauma significant loss consciousness , Parkinson 's Disease , Epilepsy , Alzheimer 's Dementia , Huntington 's Disease ) . 2 . Any absolute contraindication natalizumab , per natalizumab SPC 3 . Current recent ( last 3 month ) infection , history significant infection , immunocompromised state 4 . Previous use natalizumab previous use monoclonal antibody . 5 . Ongoing longstanding use oral steroid nonsteroidal antiinflammatory drug . 6 . Pregnancy and/or breastfeed . 7 . Substance dependence/abuse cigarette .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>